Improving quality of life through innovations in urology.
Get news and information for
healthcare professionals
Urovant Sciences
Vibegron
Our lead product candidate, vibegron, is an investigational oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS).
Latest News
The latest posts and articles
-
Urovant Sciences Announces Topline Data from...
on November 24, 2020
Key secondary endpoint of Global Improvement Scale (GIS) showed numerical differences in favor of […]
Read Latest Post -
Urovant Sciences Announces Positive Clinical...
on November 19, 2020
Extension study demonstrates favorable results in long term treatment of overactive bladder with […]
Read Latest Post -
Urovant Sciences Enters Into Definitive...
on November 12, 2020
Urovant Sciences Shareholders to Receive $16.25 per share in cash Urovant Special Independent […]
Read Latest Post
View more
Copyright 2020 © All Rights Reserved